Abbott Laboratories reported second-quarter adjusted earnings of $1.31 a share Thursday, ahead of the $1.28 analysts expected, on revenue of $12.59 billion that also edged past estimates. Reported sales grew 13% from a year ago — 4.8% on a comparable basis — and gross margin improved a full percentage point to 58% of sales. Management raised full-year adjusted EPS guidance to $5.45–$5.60 from $5.38–$5.58, putting the new midpoint above Wall Street’s consensus. The stock closed up nearly 11%, one of the best performers in an S&P 500 that fell half a percent as the chip selloff rolled into a second day.
The engine room was unglamorous: nutrition, diagnostics, electrophysiology, and cancer testing — the businesses management flagged as the drivers of second-half growth. None of them headline a keynote. All of them throw off the kind of margin that lets a company raise its floor and its ceiling at once, which is precisely what the guidance move did: the bottom of the new range sits above where the old one started.
The context is what makes the move instructive. This is the same week Netflix grew 13% and got sold 9% for merely hitting its numbers, and the same morning UnitedHealth rallied 8% on its own beat-and-raise. The pattern across earnings season is now unmistakable: matching expectations is treated as a miss, and raising guidance is the only thing being paid for. Abbott and UnitedHealth raised; both outran a falling tape. Netflix reiterated; it lost a tenth of its value overnight.
Our take: Healthcare is quietly becoming the destination for money rotating out of the AI trade. It’s underowned, it’s cheap relative to tech, and this week it produced the two best large-cap earnings reactions in the index. But be precise about what worked: Abbott didn’t just beat — it raised the floor of its full-year range. In a market this twitchy, guidance is the product and the quarter is the packaging. That cuts both ways: any healthcare name that reports a clean quarter but holds its outlook flat should expect the Netflix treatment, not the Abbott one.
What to watch
- Whether the rotation has legs. Two healthcare beat-and-raises in one day is a pattern; two weeks of them is a repricing. Managed-care and device peers report through late July — their reactions will show if the sector bid is real or just relief.
- Margin durability. Abbott’s raise leans on a 100-basis-point gross margin gain. If that holds through Q3, the new guidance midpoint starts looking conservative.
- The guidance-raise premium. If in-line reports keep getting sold across sectors, positioning ahead of earnings gets dangerous — the market is paying for the outlook, not the print.